Payment overview · 2025
General Payments
$37.20
4 reported records · 2 companies
Healthcare provider profile · identity verified
Piotr Lazowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · PLYMOUTH, MA · NPI 1386691012
Verified facts
What the public records show
CMS Open Payments records show Piotr Lazowski, MD received $37.20 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 91.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.04 | 91.5% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $3.16 | 8.5% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.04 | 1 |
| Education | $3.16 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $34.04 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $3.16 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Calcitriol | Calcitriol | 686 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 150 |
| Losartan Potassium | Losartan Potassium | 589 | 181 |
| Lisinopril | Lisinopril | 581 | 140 |
| Furosemide | Furosemide | 546 | 124 |
| Spironolactone | Spironolactone | 519 | 139 |
| Trazodone Hcl | Trazodone Hcl | 446 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 97 |
| Eliquis | Apixaban | 425 | 40 |
| Nifedipine Er | Nifedipine | 396 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 382 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 65 |
| Gabapentin | Gabapentin | 367 | 54 |
| Farxiga | Dapagliflozin Propanediol | 332 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 53 |
| Potassium Chloride | Potassium Chloride | 288 | 62 |
| Metformin Hcl | Metformin Hcl | 277 | 61 |
| Sertraline Hcl | Sertraline Hcl | 269 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 43 |
| Allopurinol | Allopurinol | 222 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 179 | 21 |
| Clonidine Hcl | Clonidine Hcl | 176 | 40 |
| Mirtazapine | Mirtazapine | 175 | 33 |
| Levetiracetam | Levetiracetam | 170 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 165 | 48 |
| Divalproex Sodium | Divalproex Sodium | 149 | 20 |
| Omeprazole | Omeprazole | 149 | 45 |
| Risperidone | Risperidone | 144 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 29 |
| Famotidine | Famotidine | 136 | 23 |
| Olanzapine | Olanzapine | 134 | 18 |
| Jardiance | Empagliflozin | 130 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 22 |
| Simvastatin | Simvastatin | 124 | 33 |
| Januvia | Sitagliptin Phosphate | 120 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 18 |
| Potassium Citrate Er | Potassium Citrate | 113 | 30 |
| Carvedilol | Carvedilol | 103 | 23 |
| Kerendia | Finerenone | 99 | 24 |
| Warfarin Sodium | Warfarin Sodium | 98 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 19 |
| Torsemide | Torsemide | 96 | 25 |
| Donepezil Hcl | Donepezil Hcl | 89 | 15 |
| Xifaxan | Rifaximin | 89 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 87 | 25 |
| Sevelamer Carbonate | Sevelamer Carbonate | 85 | 37 |
| Xarelto | Rivaroxaban | 85 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 84 | 26 |
| Prednisone | Prednisone | 80 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 17 |
| Lamotrigine | Lamotrigine | 78 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 15 |
| Klor-Con M20 | Potassium Chloride | 73 | 27 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 72 | 16 |
| Finasteride | Finasteride | 72 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 30 |
| Atenolol | Atenolol | 69 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Eplerenone | Eplerenone | 69 | 20 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 63 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 12 |
| Baclofen | Baclofen | 59 | suppressed |
| Latanoprost | Latanoprost | 58 | suppressed |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Paricalcitol | Paricalcitol | 55 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Valsartan | Valsartan | 50 | 16 |
| Calcium Acetate | Calcium Acetate | 49 | 16 |
| Cinacalcet Hcl | Cinacalcet Hcl | 49 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | suppressed |
| Glipizide Er | Glipizide | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 14 |
| Humalog | Insulin Lispro | 44 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 43 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 19 |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 43 | 12 |
| Haloperidol | Haloperidol | 42 | suppressed |
| Ozempic | Semaglutide | 42 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 13 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | 22 |
| Nyamyc | Nystatin | 36 | 15 |
| Timolol Maleate | Timolol Maleate | 35 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Chlorthalidone | Chlorthalidone | 32 | 14 |
| Pregabalin | Pregabalin | 32 | 12 |
| Topiramate | Topiramate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 18 |
| Bumetanide | Bumetanide | 30 | suppressed |
| Lumigan | Bimatoprost | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 24 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Procrit | Epoetin Alfa | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 14 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | 11 |
| Lactulose | Lactulose | 24 | 11 |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 19 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Caplyta | Lumateperone Tosylate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Risperidone Er | Risperidone Microspheres | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Brilinta | Ticagrelor | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Phenytoin | Phenytoin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.20 · 4 records | Otsuka America Pharmaceutical, Inc. | Filspari, VOYXACT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error